Research Topics
| Vaishali SanchorawalaSummaryAffiliation: Boston University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialVaishali Sanchorawala
Haematologica 98:789-92. 2013..In conclusion, this combination is associated with significant myelosuppression leading to dose modifications and producing minor hematologic responses in AL amyloidosis. http://clinicaltrials.gov/ct2/show/NCT00679367...
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosisV Sanchorawala
Department of Medicine corrected Stem Cell Transplantation Program, Section of Hematology Oncology, Boston University School of Medicine corrected Boston, MA, USA
Bone Marrow Transplant 40:557-62. 2007..The median survival for all patients enrolled on the trial has not yet been reached. Thus, tandem cycles of HDM/SCT can increase the proportion of patients who achieve an HCR...- High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trialV Sanchorawala
Hematology and Stem Cell Transplant Programs, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 33:381-8. 2004.... - Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosisV Sanchorawala
Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 36:597-600. 2005.... - An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosisVaishali Sanchorawala
Section of Hematology Oncology in the Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Amyloid 14:261-9. 2007..This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined... - Light-chain (AL) amyloidosis: diagnosis and treatmentVaishali Sanchorawala
Department of Medicine, Section of Hematology Oncology, Boston University Medical Center, Boston, Massachusetts, USA
Clin J Am Soc Nephrol 1:1331-41. 2006..This review outlines approaches to diagnosis, assessment of disease severity, and treatment of AL amyloidosis... - AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomesV Sanchorawala
Department of Medicine, Boston University Medical Center, Boston, MA, USA
Am J Hematol 81:692-5. 2006..However, high-dose melphalan and stem cell transplantation was the primary therapy in 5 patients, and each of these patients had prolonged survival, ranging from 36 to 102 months... 
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantationVaishali Sanchorawala
Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
Blood 110:3561-3. 2007..001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR...- Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosisVaishali Sanchorawala
Department of Medicine, Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
Br J Haematol 117:886-9. 2002..This regimen appeared to be effective in inducing haematological responses in patients who received total doses of melphalan > 300 mg... - Oral cyclic melphalan and dexamethasone for patients with AL amyloidosisVaishali Sanchorawala
Section of Hematology Oncology, Department of Medicine, Boston University School of Medicine, 820 Harrison Avenue, Boston, MA 02118, USA
Clin Lymphoma Myeloma Leuk 10:469-72. 2010..However, only selected patients with AL amyloidosis are eligible for HDM/SCT because of amyloid-associated organ dysfunction... - Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trialVaishali Sanchorawala
Department of Medicine, F 302, 732 Harrison Ave, Boston University Medical Center, MA 02118, USA
Blood 109:492-6. 2007..Findings from this trial indicate that lenalidomide can be effective in treating AL amyloidosis... - Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65David C Seldin
Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
Blood 108:3945-7. 2006.... - Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantationDavid C Seldin
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Blood 104:1888-93. 2004..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR... - Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosisSaulius Girnius
Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
Ann Hematol 89:579-84. 2010..Hematologic relapses occurred in 60% of patients at a median of 1 year after HDM/SCT. In conclusion, HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it... - High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year studyMartha Skinner
Boston University School of Medicine, Boston, Massachusetts 02118, USA
Ann Intern Med 140:85-93. 2004..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective... - Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature reviewMartin Tam
Graduate Medical Sciences Division, Boston University School of Medicine, Boston, Massachusetts, USA
Amyloid 16:103-7. 2009..A literature review of spontaneous liver rupture in patients with amyloidosis is presented... - Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosisAmit Fadia
The Renal Section, Stem Cell Transplant Program of the Hematology/Oncology Section, and Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
Kidney Int 63:1868-73. 2003..9 years. CONCLUSION: ARF is a frequent but often reversible complication of HDM/SCT for AL amyloidosis. Specific clinical and treatment-related factors are associated with the development of this complication... - Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosisDavid C Seldin
Boston University Medical Center, Boston Medical Center, MA, USA
Clin Lymphoma 3:241-6. 2003..No complete hematologic responses were seen, but 25% of patients had a significant reduction in Bence-Jones proteinuria. Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population... - High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal diseaseLiam F Casserly
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Kidney Int 63:1051-7. 2003..This treatment should be considered for patients with AL amyloidosis-associated ESRD... - Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver diseaseSaulius Girnius
Department of Medicine, Boston University School of Medicine, Boston University School of Public Health, Boston, MA, USA
Haematologica 94:1029-32. 2009..In conclusion, hepatic disease improves in almost 2/3 patients treated with high-dose intravenous melphalan and autologous stem cell transplantation who have a complete or partial hematologic response to treatment... - Association of acquired von Willebrand syndrome with AL amyloidosisCynthia A Kos
Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA
Am J Hematol 82:363-7. 2007..AVWS should be considered in AL amyloidosis patients with hemorrhagic diatheses and normal clotting factor levels... - Kidney dysfunction during lenalidomide treatment for AL amyloidosisRichard Specter
Renal Section, Boston University School of Medicine, Boston, MA, USA
Nephrol Dial Transplant 26:881-6. 2011..The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide... - Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature reviewStephanie B Tsai
Amyloid Treatment and Research Program, Boston Medical Center, 820 Harrison Avenue, Boston, MA, USA
Amyloid 18:160-4. 2011..Contemporary testing should aim to detect both forms of cardiac amyloidosis, which may impact management and prognosis... - Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatmentDavid C Seldin
Amyloidosis Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston Medical Center, K5, 72 East Concord Street, Boston, MA 02118, USA
Heart Fail Clin 7:385-93. 2011..Growing numbers of treatment options exist for these diseases, and timely diagnosis and institution of therapy is essential for preservation of cardiac function... - Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsMaria Teresa Cibeira
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Blood 118:4346-52. 2011..9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR... - An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosisV Sanchorawala
Stem Cell Transplant Program of the Section of Hematology and Oncology, Medical Center, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
Bone Marrow Transplant 28:637-42. 2001.... - Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature reviewBenjamin Freeman
Section of Hematology and Oncology, Boston University School of Medicine, Boston, MA, USA
Amyloid 19:156-60. 2012..A literature review of thrombembolic complications in patients with amyloidosis is presented... - Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftmentAndrew J Cowan
Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, Massachusetts
Biol Blood Marrow Transplant 18:1935-8. 2012..Thus, our data indicate that although amyloid involvement of the bone marrow is common, it does not negatively affect stem cell mobilization or neutrophil and platelet engraftment after HDM-SCT... - Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosisHarun Akar
Amyloid Treatment and Research Program at Boston Medical Center, Boston University School of Medicine, Boston, MA, 02118, USA
Amyloid 12:210-5. 2005..After a histologic tissue diagnosis of amyloidosis, determining the type as AL amyloidosis relies on a panel of hematologic tests to determine light chain clonality and the exclusion other forms of amyloidosis... - Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosisJohn L Berk
Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
Chest 124:969-77. 2003..We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease... - Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experienceAndrew J Cowan
Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA, USA
Haematologica 98:141-6. 2013..Although a rare manifestation of amyloidosis, staining for amyloid should be considered in patients undergoing gastrointestinal biopsy who have unexplained chronic gastrointestinal symptoms... - Macroglossia - not always AL amyloidosisAndrew J Cowan
Department of Medicine, Amyloid Treatment and Research Program, Boston University School of Medicine, Boston Medical Center, Massachusetts, USA
Amyloid 18:83-6. 2011.... - Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failureBimalangshu R Dey
Massachusetts General Hospital, Boston, MA, USA
Transplantation 90:905-11. 2010..Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure... - Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal diseaseL M Dember
Renal Section, EBRC 504, Boston University Medical Center, 650 Albany Street, Boston, MA 02118, USA
Ann Intern Med 134:746-53. 2001..The impact of this treatment on associated renal disease is not known... - Diaphragm paralysis in primary systemic amyloidosisJohn L Berk
The Pulmonary Center, Boston University School of Medicine, MA 02118, USA
Amyloid 12:193-6. 2005..Nocturnal non-invasive ventilation lowered arterial carbon dioxide levels and improved daytime dyspnea. This is the first case associating AL amyloid-induced neuropathy with diaphragm dysfunction... - Localized amyloidosis of the breast: a case seriesMarjory Charlot
Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, MA, USA
Amyloid 18:72-5. 2011..Thus, other than excisional biopsy to exclude malignancy, no systemic therapy is indicated for this disorder... - Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosisR L Comenzo
Department of Medicine, Stem Cell Transplant Program, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA
Br J Haematol 104:553-9. 1999..The 100 d mortality was 20%. In conclusion, no definitive differences were identified between the mobilization regimens and IDM was an active regimen in AL for selected patients... - Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapyE B Choufani
Section of Hematology and Oncology, Department of Medicine, Boston Medical Center, Boston, MA, USA
Blood 97:1885-7. 2001..Thus, aggressive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the amelioration of amyloid-related factor X deficiency... - Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reactionM Rosenzweig
Stem Cell Transplant Program in the Section of Hematology Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
Bone Marrow Transplant 45:21-4. 2010..We conclude that an unusual cytokine-mediated febrile reaction can occur in patients with AL amyloidosis exposed to a second cycle of high-dose melphalan, which we have termed a 'melphalan recall' reaction... - Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosisB Oran
Department of Medicine, Boston University Medical Center, Boston, MA, USA
Bone Marrow Transplant 35:567-75. 2005..Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue... - Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantationK Weichman
Section of Hematology/Oncology, Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
Bone Marrow Transplant 38:339-43. 2006..In our experience, HDM/SCT is a feasible and effective treatment approach for these disorders... - Amyloidomics comes of ageDavid C Seldin
Boston University School of Medicine, USA
Blood 119:1795-6. 2012..In this issue of Blood, Brambilla et al report a new methodology for accomplishing the key third step in this process... - Cardiac amyloidosis: evolving approach to diagnosis and managementHans K Meier-Ewert
Section of Cardiovascular Medicine and Amyloid Treatment and Research Program, Boston University School of Medicine, C 8, 88 East Newton Street, Boston, MA, 02118, USA
Curr Treat Options Cardiovasc Med 13:528-42. 2011..For familial amyloid derived from variant TTR, liver transplantation is the one validated treatment; however, small molecule therapeutic agents now in clinical trials appear capable of slowing or halting TTR amyloid deposition... - A case of atypical light chain deposition disease--diagnosis and treatmentDavid J Salant
Renal Section, Department of Medicine, University Medical Center, Boston, MA, USA
Clin J Am Soc Nephrol 2:858-67. 2007 - Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosisG Akpek
Section of Hematology and Oncology, Department of Medicine, Boston University Medical Center, Boston, MA, USA
Bone Marrow Transplant 28:1105-9. 2001.... - Spontaneous rupture of the spleen in AL amyloidosisB Oran
Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA
Am J Hematol 74:131-5. 2003..All four patients underwent splenectomy without significant postoperative complications. Splenic rupture in AL amyloidosis as a complication of aggressive treatment with HDM/SCT has not been reported previously... - Azotemia associated with use of lenalidomide in plasma cell dyscrasiasEric D Batts
University Hospitals Case Medical Center and Ireland Cancer Center and Case Comprehensive Cancer Center, Cleveland, OH, USA
Leuk Lymphoma 49:1108-15. 2008..We advise careful monitoring of renal function after initiation of lenalidomide in this setting... - Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004Morie A Gertz
Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 79:319-28. 2005..We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL... - Adapting to AL amyloidosisDavid C Seldin
Haematologica 91:1591-5. 2006